During last few years, immunotherapy has emerged out to be promising cancer therapy in addition to surgery, chemotherapy and radiotherapy. Immunotherapy has shown a significant therapeutic effect in wide range of human cancer by using the immune system to eliminate cancer cells
Global Personalized Cancer Vaccine Market Outlook 2028 Report Highlights:
- Developmental Cost Analysis of a Personalized Cancer Vaccine
- Biomarkers Importance In Personalized Vaccines
- Ongoing Clinical Trials on Personalized Cancer Vaccine
- Immune Checkpoint Biomarkers Preventing Tumor Growth
- Personalized Cancer Vaccine Market Dynamics
- Advancements in the Personalized Cancer Vaccine
- Ongoing Market Trends in Personalized Cancer Vaccine Market
Download Report
https://www.kuickresearch.com/report-personalised-cancer-vaccines-market-trials
During last few years, immunotherapy has emerged out to be promising cancer therapy in addition to surgery, chemotherapy and radiotherapy. Immunotherapy has shown a significant therapeutic effect in wide range of human cancer by using the immune system to eliminate cancer cells. With the introduction of high throughput screening, next generation sequencing and identification of neoantigens, immunotherapy based on neoantigens has become new hotspot for investments among the pharmaceutical companies. Neoantigens are mainly tumor-specific antigens generated by mutations in tumor cells, which are only expressed in tumor cells. Among all immunotherapeutic approaches, neoantigen based vaccines have gained considerable momentum in the global market. As these neoantigens are specific for a particular individual, personalized neoantigen vaccines have been developed by pharmaceutical companies which are mainly present in clinical development.
Although no personalized cancer vaccine has been entered the market, the pipeline of these are highly crowded which are expected to gain entry into the market during the forecast period. For instance, Moderna in collaboration with Merck has developed its novel mRNA personalized cancer vaccine (PCV), mRNA4157 which is combination of validated defined neoantigens, predicted neoepiotopes and mutations in driver genes into a single mRNA concatemer (mRNA4650). The vaccine is being evaluated as monotherapy and combination therapy in two clinical trials. Another, BioNTech subsididary Nenon Therapeutics have developed NEO-PV-01 which is a personalized neoantigen vaccine to target neoepitopes encoded by somatic mutation in patient’s tumor. NEO-PV-01 is a personal neoantigen vaccine of up to 20 peptides designed based on patient’s neoantigen and HLA profile that is directed at inducing tumor specific T cell response to neoantigens.
The companies are also reporting their encouraging results from the clinical trials which suggest that the entry of these vaccines will transform the overall paradigm of cancer therapeutics. For example, AV-GBM-1 developed by Aivita Biomedical is an individualized immunotherapy that is comprised of autologous dendritic cells that are full of autologous tumor neoantigens that are derived from self-renewing tumor-initiating cells that are taken from tumors following routine surgical debulking. The recent data from the glioblastoma patients shows that the investigational vaccine significantly enhanced the progression free survival and overall survival rates.
Apart from this, investigators are also utilizing the potential of personalized cancer vaccines in combination therapy to further enhance their efficacy and overcome the limitation of drug resistance. For instance, a phase-I/II study accessing the safety and tolerability of GRANITE personalized immunotherapy in combination with Tecentriq and Yervoy in solid tumors including colorectal cancer. The results from the study continue to demonstrate a correlation between molecular response and overall survival. On the basis of these encouraging results, the company will conduct GRANITE-CRC-IL clinical trial which is phase-II/III randomized, open label study evaluating GRANITE vaccine as first line of maintenance therapy in combination with Tecentriq as well as Yervoy for the treatment of patients with new diagnosed metastatic, microsatellite-stable colorectal cancer (MSS-CRC) who received fluoropyrimidine, oxaliplatin and bevacizumab (FOLFOX-bevacizumab) induction therapy.
Rising investment among the pharmaceutical companies associated with the increase in prevalence of cancer and huge demand of 8individulaized targeted therapy are the major factors boosting the growth of market. The global market is highly competitive and consists of several key players including Merck, Moderna, Gristone Oncology, AstraZeneca, Sanofi, AbbVie, Pfizer, Amgen, and others. These companies have also opted for strategic alliances such as collaboration, partnerships, or joint ventures to maintain a strategic edge in the global market.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com